

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2616824/jia-zhong-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24 papers	184 citations	7 h-index	12 g-index
27 ext. papers	281 ext. citations	3.7 avg, IF	2.35 L-index

#	Paper	IF	Citations
24	Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 639892	5.6	5
23	A phase II study of vorolanib in combination with toripalimab in patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21053-e21053	2.2	1
22	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , 2021 , 9, 33	3.2	7
21	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. <i>Cancer Cell International</i> , 2020 , 20, 590	6.4	
20	Analysis of MET kinase domain rearrangement in NSCLC. <i>Lung Cancer</i> , 2020 , 145, 140-143	5.9	5
19	Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. <i>Thoracic Cancer</i> , 2020 , 11, 1149-1159	3.2	2
18	Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. <i>Frontiers in Oncology</i> , 2020 , 10, 626	5.3	5
17	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 892-901	12.9	34
16	A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database. <i>BMC Cancer</i> , 2020 , 20, 666	4.8	8
15	Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. <i>Frontiers in Oncology</i> , 2020 , 10, 1137	5.3	3
14	Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. <i>BMC Cancer</i> , 2020 , 20, 793	4.8	6
13	Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database. <i>Thoracic Cancer</i> , 2019 , 10, 1193-1202	3.2	4
12	Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. <i>Thoracic Cancer</i> , 2019 , 10, 1788-1797	3.2	5
11	Optimal first-line treatment for advanced thymic carcinoma. <i>Thoracic Cancer</i> , 2019 , 10, 2081-2087	3.2	6
10	ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. <i>Thoracic Cancer</i> , 2019 , 10, 2088-2095	3.2	14
9	cfDNA analysis to reveal association of genomic features with chemotherapy response and survival in patients with pulmonary large-cell neuroendocrine carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14555-e14555	2.2	
8	Survival comparison of right and left side non-small cell lung cancer in stage I-IIIa patients: A Surveillance Epidemiology and End Results (SEER) analysis. <i>Thoracic Cancer</i> , 2019 , 10, 459-471	3.2	8

7	Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018 , 9, 291-297	3.2	4
6	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , 2018 , 9, 1166-1173	3.2	7
5	Survival difference between Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017 , 29, 553-560	3.8	10
4	Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1766-1778	8.9	35
3	EML4-ALK rearrangement detection in malignant pleural effusions from patients with advanced non-small cell lung cancer: Feasibility and predictive value.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e19094-e19094	2.2	2
2	Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2014 , 5, 509-16	3.2	9
1	Synchronous breast cancer and breast lymphoma: two case reports and literature review. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2014 , 26, 355-9	3.8	3